Literature DB >> 17429594

Approach to the evaluation of the GH/IGF-axis in patients with pituitary disease: which test to order.

Brian Roberts1, Laurence Katznelson.   

Abstract

The diagnosis of adult growth hormone deficiency (AGHD) and acromegaly involves assessment of serum growth hormone (GH) and insulin-like growth factor-1 (IGF-1) concentrations. The diagnosis of AGHD typically requires a provocative test of GH reserve, but is supported by demonstration of low-serum IGF-1 levels. Therapeutic monitoring of rhGH replacement is performed utilizing measurement of serum IGF-1 concentrations. In patients with suspected acromegaly, the diagnosis is confirmed by elevated serum IGF-1 levels and further validated by the presence of elevated GH levels both before and following an oral glucose load. A goal of acromegaly therapy is to normalize IGF-1 concentrations, and, depending on the therapeutic modality, GH levels as well. Using case based clinical scenarios, we have presented a standard approach to the biochemical diagnosis and therapeutic monitoring of these disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17429594     DOI: 10.1007/s11102-007-0026-x

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   3.599


  40 in total

1.  Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population.

Authors:  M L Granada; J Murillo; A Lucas; I Salinas; M A Llopis; I Castells; M Foz; A Sanmartí
Journal:  Eur J Endocrinol       Date:  2000-03       Impact factor: 6.664

Review 2.  Update on the diagnosis of GH deficiency in adults.

Authors:  Roger Abs
Journal:  Eur J Endocrinol       Date:  2003-04       Impact factor: 6.664

Review 3.  Long-term experience with GH replacement therapy: efficacy and safety.

Authors:  John P Monson
Journal:  Eur J Endocrinol       Date:  2003-04       Impact factor: 6.664

4.  Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.

Authors:  S E Hankinson; W C Willett; G A Colditz; D J Hunter; D S Michaud; B Deroo; B Rosner; F E Speizer; M Pollak
Journal:  Lancet       Date:  1998-05-09       Impact factor: 79.321

Review 5.  Clinical aspects of growth hormone deficiency in adults.

Authors:  H de Boer; G J Blok; E A Van der Veen
Journal:  Endocr Rev       Date:  1995-02       Impact factor: 19.871

6.  The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.

Authors:  B A Bengtsson; R Abs; H Bennmarker; J P Monson; U Feldt-Rasmussen; E Hernberg-Stahl; B Westberg; P Wilton; C Wüster
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

7.  Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency?

Authors:  Mark L Hartman; Brenda J Crowe; Beverly M K Biller; Ken K Y Ho; David R Clemmons; John J Chipman
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

Review 8.  Human growth hormone and human aging.

Authors:  E Corpas; S M Harman; M R Blackman
Journal:  Endocr Rev       Date:  1993-02       Impact factor: 19.871

9.  Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.

Authors:  S Grinspoon; D Clemmons; B Swearingen; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958

10.  Comparison between insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) measurement in the diagnosis of growth hormone deficiency.

Authors:  Y Hasegawa; T Hasegawa; T Aso; S Kotoh; Y Tsuchiya; O Nose; Y Ohyama; K Araki; T Tanaka; S Saisyo
Journal:  Endocr J       Date:  1993-04       Impact factor: 2.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.